Department of Medical Oncology, VU University Medical Center, Amsterdam.
Department of Internal Medicine, Spaarne Hospital, Hoofddorp.
Ann Oncol. 2014 Oct;25(10):1914-1918. doi: 10.1093/annonc/mdu052. Epub 2014 Feb 25.
The number of older patients with cancer is increasing. Standard clinical evaluation of these patients may not be sufficient to determine individual treatment strategies and therefore Geriatric Assessment (GA) may be of clinical value. In this review, we summarize current literature that is available on GA in elderly patients with solid malignancies who receive chemotherapy. We focus on prediction of treatment toxicity, mortality and the role of GA in the decision-making process.
We conducted a systematic search in PubMed. Studied populations needed to fulfill the following criteria: 65 years or older, diagnosis of solid malignancy, treatment with chemotherapy, submission to GA, either designed to study prediction of treatment toxicity or mortality or to evaluate the role of GA in the decision-making process.
Our search provided 411 publications. Thirteen met the predefined criteria. These studies revealed: (i) up to 64% of elderly patients suffer from severe toxicity caused by polychemotherapy, (ii) Nutritional status, functionality and comorbidity are often associated with worse outcome, (iii) GA reveals (unknown) geriatric problems in more than 50% of elderly patients with cancer and (iv) 21%-53% of chemotherapy regimens are being modified based on GA.
In geriatric oncology, an accurate predictive test to guide anticancer treatment in order to prevent serious toxicity is needed. The value of GA in predicting toxicity and mortality in older patients with cancer undergoing treatment with chemotherapy has not been proven. It may be valuable in revealing geriatric problems but current evidence for its usefulness to guide treatment decisions in this setting is limited. However, we are convinced that GAs should be carried out to optimize treatment strategies in elderly patients with cancer to improve treatment efficacy and minimize toxicity.
患有癌症的老年患者人数正在增加。对这些患者进行标准的临床评估可能不足以确定个体治疗策略,因此老年综合评估(GA)可能具有临床价值。在这篇综述中,我们总结了目前关于接受化疗的老年实体恶性肿瘤患者 GA 的可用文献。我们重点介绍了 GA 在预测治疗毒性、死亡率和 GA 在决策过程中的作用。
我们在 PubMed 中进行了系统搜索。研究人群需要满足以下标准:年龄 65 岁或以上、诊断为实体恶性肿瘤、接受化疗治疗、接受 GA,无论是旨在研究预测治疗毒性或死亡率,还是评估 GA 在决策过程中的作用。
我们的搜索提供了 411 篇出版物。符合既定标准的有 13 篇。这些研究揭示了:(i)多达 64%的老年患者因多药化疗而遭受严重毒性,(ii)营养状况、功能和合并症通常与较差的结果相关,(iii)GA 揭示了 50%以上患有癌症的老年患者存在(未知)老年问题,以及(iv)21%-53%的化疗方案基于 GA 进行了修改。
在老年肿瘤学中,需要一种准确的预测性测试来指导抗癌治疗,以防止严重毒性。GA 在预测接受化疗的老年癌症患者的毒性和死亡率方面的价值尚未得到证实。它可能有助于揭示老年问题,但目前其在指导该人群治疗决策方面的有用性证据有限。然而,我们坚信,应该进行 GA 以优化老年癌症患者的治疗策略,提高治疗效果并最小化毒性。